Nevertheless, it seems certain that this also reflects disease-specific pharmacological actions—for example, Raf kinase inhibition is therapeutic in LRRK2-based PD models, but ineffective in α-synuclein- and 6-OHDA-based PD models [60]. The gene discussed is LRRK2; the disease is Parkinson disease.